Skip to main content

Kardigan, Inc 10-Q for FY2026 Q3

Kardigan, Inc. (KARD)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Kardigan, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$58.57M
compared with a net loss of $60.16M a year earlier
Diluted EPS
-$0.64
compared with -$4.43 a year earlier